Leuprolide Acetate
Brand Names: Lutrate Depot, Lupron Depot, Fensolvi, Eligard, Lupron Depot-Ped, Vabrinty
Methodology & AI Transparency ⓘ
Leuprolide Acetate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Leuprolide Acetate is an FDA-monographed gonadotropin releasing hormone receptor agonist (Rx, RxNorm 545835).
- 2 Real-world patient consensus: 80% patient "Worth It" rating across 20 anonymous logs for Leuprolide Acetate (RxNorm 545835).
- 3 Typical cash cost range: Public pharmacy ledger: $64.02 low cash benchmark vs. $156.85 chain retail average ($5203.8615/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Leuprolide Acetate tolerability events: nausea (8.7%), headache (8.3%), dizziness (5.7%).
Ask our AI Specialists anything about Leuprolide Acetate
Leuprolide Acetate Mechanism, CYP450 Pathways & DailyMed Monograph
Leuprolide Acetate is an FDA-monographed gonadotropin releasing hormone receptor agonist (Rx, RxNorm 545835). Indications and usage: Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. Listed under NDC 70771-1687 (SPL 2026-02-09).
CLINICAL PHARMACOLOGY Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs.
Pharmacokinetic profiling of Leuprolide Acetate demonstrates an elimination half-life of Approximately 3–9 hours terminal plasma half-life for Leuprolide Acetate with Estimated 65%–77% oral systemic absorption for Leuprolide Acetate systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of leuprolide acetate coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–4 hours post-dose for leuprolide acetate.
Titration schedules for Leuprolide Acetate (Kit → 45 mg/.375mL Injection, Suspension, Extended Release → 7.5 mg/.25mL Injection, Suspension, Extended Release → 22.5 mg/.375mL Injection, Suspension, Extended Release → 1 mg/.2mL Injection) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to leuprolide acetate or leuprolide acetate excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-02-09 leuprolide acetate spl; real-world patient logs highlight nausea (8.7% of reports), headache (8.3% of reports), dizziness (5.7% of reports) alongside a 80.00% Worth-It consensus.
Avoid overlapping gonadotropin releasing hormone receptor agonist prescriptions alongside Leuprolide Acetate to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Leuprolide Acetate; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Leuprolide Acetate or Leuprolide Acetate excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-02-09 Leuprolide Acetate SPL
Logged Side-Effect Incidence (20 Reports)
Leuprolide Acetate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leuprolide Acetate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on A crossover study of triptorelin and leuprorelin Both drugs are equally potent in down-regulating the pituitary-ovarian function, and their side effects are similar. Fertility and sterility • 2000-08-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 10927048 ↗ |
| Can This Approach Help? Inside the Latest Research on Pharmacologically induced hypogonadism and sexual function in healthy young women No predictors of response were identified except for levels of sexual function at baseline. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology • 2009-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 18354393 ↗ |
| Can This Approach Help? Inside the Latest Research on Ulipristal acetate compared with leuprorelin acetate for Japanese women with No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group. Fertility and sterility • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33715871 ↗ |
| Can This Approach Help? Inside the Latest Research on Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces Safety profiles of both medications were comparable, although menses returned earlier in patients taking REL, a huge benefit for women who plan to conceive after treatment. Fertility and sterility • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34895700 ↗ |
| New Insights on Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate: What a 934-Participant Study Found Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reduction. European urology • 2023-12-15 • Phase III Randomized Trial | N = 934 | 87/100 | PMID 37833178 ↗ |
Leuprolide Acetate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5203.8615/unit (~$156115.85/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $64.02 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $156.85 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $73.62 / mo | View logs ↓ |
Leuprolide Acetate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Leuprolide Acetate RxNorm Concept ID | 545835 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5203.8615 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $156.85 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $64.02 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 80.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Leuprolide Acetate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Leuprolide Acetate integrating DailyMed SPL (2026-02-09), CMS NADAC ($5203.8615/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Leuprolide Acetate community threads and patient logs by age, biological sex, dosage, and treatment duration.